Oventus Medical Ltd (ASX:OVN) is pleased to provide a copy of its latest newsletter for investors.
Key highlights from the newsletter include:
- An overview of the initiatives underway to roll Oventus' technology out into the dental and sleep channels in Australia and the USA
- An introduction to new Oventus USA team members, including an interview with Robin Randolf, Vice President of Marketing and Operations for Oventus in North America
- A product, research and development (R&D) and clinical trials update; and
- A summary of Oventus' recent and forthcoming events
To view a copy of the newsletter, investors can visit the Investor News section on the Oventus website or copy and paste the following link into their web browser: http://www.abnnewswire.net/lnk/O74V5870
About the Oventus O2Vent airway technology
The Oventus O2Vent is an oral appliance device which brings the lower jaw forward (a process commonly referred to as mandibular advancement) and incorporates an opening to the oral cavity to allow breathing through the device airway, bypassing obstructions of the nose and soft palate, stabilising the tongue base and reducing airway collapsibility during sleep.
Further information can be found on our website: http://oventus.com.au/how-it-works/
To view the newsletter, please visit:
Mr Neil Anderson Managing Director and CEO M: +61-403-003-475 Jane Lowe IR Department M: +61-411-117-774 or E: firstname.lastname@example.org
News Provided by ABN Newswire